" class="no-js "lang="en-US"> David Meek - Medtech Alert
Wednesday, November 13, 2024
David Meek

David Meek

About David Meek

David has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology including as chief executive officer (CEO) of Ipsen, a leading global biopharmaceutical company.

During his tenure as CEO at Ipsen, David led the transformation of the company into a high-growth and leading global biopharmaceutical organization through the expansion of the oncology portfolio in the U.S. and Europe, and growing the R&D portfolio through internal and external innovation.

David most recently served as president, CEO and board member of FerGene focused on developing an innovative gene therapy for bladder cancer. His prior leadership roles include serving as executive vice president and president of oncology at Baxalta from 2014 to 2016, until its acquisition by Shire plc. He was also chief commercial officer of Endocyte from 2012 to 2014. Prior to that, Mr. Meek served in various executive leadership roles at Novartis Pharma and Novartis Oncology after beginning his career at Johnson & Johnson and Janssen from 1989 to 2004. He holds a Bachelor of Arts from the University of Cincinnati. Prior to his biopharma career, David was an active duty commissioned officer in the U.S. Army achieving the rank of Captain.

David has also served on the boards of Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), and currently serves on the boards of uniQure N.V., and Entasis Therapeutics Holdings Inc.

Related Story

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

May 17 2022

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as […]